Document:

ccxi-ex102_481.htm

 

Exhibit 10.2

 

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

PRODUCT AGREEMENT

(Includes Schedules A to D)

 

PRODUCT AGREEMENT

This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated March 18, 2020 between Patheon Pharmaceuticals Inc., and ChemoCentryx, Inc., (the “Master Agreement”), and is entered into as of the last signature date set forth below (the “Effective Date”), between Patheon Pharmaceuticals Inc., a corporation existing under the laws of the State of Delaware, having a principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237-1625 (“Patheon”) and ChemoCentryx, Inc., a corporation existing under the laws of the State of Delaware having a principal place of business at 850 Maude Avenue, Mountain View, CA 94043 USA (“Client”).

The terms and conditions of the Master Agreement are incorporated herein except to the extent this Product Agreement expressly references the specific provision in the Master Agreement to be modified by this Product Agreement.  All capitalized terms that are used but not defined in this Product Agreement will have the respective meanings given to them in the Master Agreement.

The Schedules to this Product Agreement are incorporated into and will be construed in accordance with the terms of this Product Agreement.

	
 
	
1.
	
Product List and Specifications (See Schedule A attached hereto)

	
 
	
2.
	
Minimum Order Quantity, Initial Exclusivity Period Percentage, Annual Volume, and Price (See Schedule B attached hereto).    

	
 
	
3.
	
Annual Stability Testing and Validation Activities (if applicable) (See Schedule C attached hereto) 

	
 
	
4.
	
Active Materials, Active Materials Credit Value, and Maximum Credit Value (See Schedule D attached hereto)

	
 
	
5.
	
Yearly Forecasted Volume: Not applicable

	
 
	
6.
	
Territory: United States of America and ROW

	
 
	
7.
	
Manufacturing Site: 2110 East Galbraith Road, Cincinnati, OH 45237-1625 

	
 
	
8.
	
Governing Law: (Per Section 13.17 of the Master Agreement)

	
 
	
9.
	
Inflation Index: Not applicable

	
 
	
10.
	
Currency: USD

 

 

	
 
	
11.
	
Initial Set Exchange Rate: Not applicable

	
 
	
12.
	
Product Agreement Term: This Product Agreement is effective from the Effective Date until December 31, 2026 (the “Initial PA Term”), unless earlier terminated in accordance with the Master Agreement.  Notwithstanding anything to the contrary in the Master Agreement, this Product Agreement shall automatically renew after the Initial PA Term for successive renewal terms of two Years (each, a “PA Renewal Term”) unless either party gives written notice to the other party of its intention to terminate this Product Agreement at least 12 months prior to the end of the then current term. For termination by Client under Section 8.2(d) of the Master Agreement that are effective after Year 2, Client must provide Patheon with 12 months’ prior written notice of the termination and Client will pay Patheon an early termination fee of [***] if the termination is effective after [***] through the end of [***] or an early termination fee of [***] if the termination is effective after the end of [***].   

	
 
	
13.
	
Notices: (Per Section 13.9 of the Master Agreement)

	
 
	
14.
	
Other Modifications to the Master Agreement: Not applicable

 

________________________________________

 

IN WITNESS WHEREOF, the duly authorized representatives of the parties have executed this Product Agreement as of the Effective Date set forth above.

 

PATHEON PHARMACEUTICALS INC. 

By:  /s/ Miguel Faustino

Name:  Miguel Faustino

Title:  VP & GM – Cincinnati Regional Ops

Date: 05 May 2020

 

CHEMOCENTRYX, INC.

By:  /s/ Thomas Schall

Name:  Thomas Schall

Title:  President, CEO

Date: 2020-05-08

- 2 -

 

SCHEDULE A

PRODUCT LIST AND SPECIFICATIONS

Product List

10 mg CCX-168 liquid filled hard gelatin capsules in bulk and [***] bottles (the “Product”).

 

Specifications

Prior to the start of commercial manufacturing of the Product under this Agreement, Client will give Patheon the originally executed copies of the Specifications as approved by the applicable Regulatory Authority.  If the Specifications received are subsequently amended, then Client will give Patheon the revised and originally executed copies of the revised Specifications.  Upon acceptance of the revised Specifications, Patheon will give Client a signed and dated receipt indicating Patheon’s acceptance of the revised Specifications.

 

 

- 3 -

 

SCHEDULE B

MINIMUM ORDER QUANTITY, INITIAL EXCLUSIVITY PERIOD PERCENTAGE, ANNUAL VOLUME, AND PRICE

Initial Exclusivity Period Percentage:  [***] of Client’s commercial Product supply requirements

Commercial batch size corresponds to [***] capsules 

10mg CCX-168 Capsules – Bulk Pricing

[***]

10mg CCX-168 Capsules – [***] Full Batch Bottle Pricing

[***]

10mg CCX-168 Capsules – Split Batch Pricing

[***]

Manufacturing Process:

	
 
	
•
	
The manufacturing process at Patheon will follow the process in the Master Batch Production Record approved by Client and Patheon.

[***]

Packaging Configurations:

[***]

Analytical Testing Performed:

[***] 

The following cost items are included in the Price for the Product:

[***]

The following cost items are not included in the Price for the Product:

[***]

 

 

SCHEDULE C

ANNUAL STABILITY TESTING 

Patheon and Client will agree in writing on any stability testing to be performed by Patheon on the Product.  This agreement will specify the commercial and Product stability protocols applicable to the stability testing and the fees payable by Client for this testing including the Price for the Product withdrawn for the stability testing.  

 

 

SCHEDULE D

ACTIVE MATERIALS

 

	
Active Materials
	
Supplier

	
CCX-168
	
Hovione

 

ACTIVE MATERIALS CREDIT VALUE

The Active Materials Credit Value will be as follows:

 

	
PRODUCT
	
ACTIVE MATERIALS
	
ACTIVE MATERIALS

CREDIT  VALUE

	
10mg CCX-168 Capsules
	
CCX-168
	
Client’s actual cost for Active Materials not to exceed [***] per kilogram

 

MAXIMUM CREDIT VALUE

Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for any Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below:

 

	
PRODUCT
	
MAXIMUM CREDIT VALUE

	
10mg CCX-168 Capsules
	
[***] of revenues per Year to Patheon under this Product Agreement.Exhibit

Exhibit 10.2
Amendment to Amended and Restated Shareholders Agreement
Amendment, dated as of July 29, 2020 (this “Amendment”) among Apollo Global Management, Inc., a Delaware corporation (the “Company”), AP Professional Holdings, L.P., a Cayman Islands exempted limited partnership (“Holdings” and, collectively with all other Persons (as defined herein) who become or who became parties to this Agreement as “Shareholders” in accordance with the terms of this Agreement, the “Shareholders”), BRH Holdings, L.P., a Cayman Islands exempted limited partnership (“BRH”), Black Family Partners, L.P., a Delaware limited partnership, Leon D. Black (“LB”), MJR Foundation LLC, a New York limited liability company, Marc J. Rowan (“MR”), MJH Partners, L.P., a Delaware limited partnership, Joshua J. Harris (“JH”, and together with LB and MR, the “Principals”, and each individually, a “Principal”).
WHEREAS, the Parties heretofore executed and delivered an Amended and Restated Shareholders Agreement, dated as of September 5, 2019 (the “Agreement”); and
WHEREAS, the parties now desire to enter into this Amendment to amend the Agreement as more fully set forth below;
Capitalized terms used herein but not defined herein shall have the meanings assigned to such terms in the Agreement.
NOW, THEREFORE, the Parties hereby agree as follows:
		
	1.
	Amendment to Section 1.1 of the Agreement

		
	a)
	The definition of “Exchange” is hereby amended and restated in its entirety as follows:

“Exchange” means (i) the exchange by Holdings of an Operating Group Unit for a Class A Share pursuant to the Exchange Agreement (subject to adjustment in accordance with Section 2.4 of the Exchange Agreement), and the subsequent sale of such Class A Share(s), at prevailing market prices for a Class A Share(s) (unless the Person requesting such Exchange is willing to accept a lower price, e.g., to effect a block trade), (ii) a redemption of Operating Group Units initiated by the Company or any of its Subsidiaries, solely upon the Company’s election, in which any limited partner of Holdings elects to participate, (iii)  a sale by Holdings of Operating Group Units, (iv) in the event of a Non-Pro Rata Exchange or, except in connection with a transaction described in clause (v) below, a Pro Rata Exchange, an In-Kind Exchange Distribution (including the corresponding exchange of an Operating Group Unit for Class A Shares in accordance with the Exchange Agreement) or (v) at the option of Holdings GP, in the event of a Pro Rata Exchange in connection with a transaction that constitutes an Extraordinary Transaction (as defined in the Agreement Among Principals) pursuant to clause (i) of the definition thereof or a recapitalization, restructuring, roll-up or other similar transformative transaction as a result of which the entities (other than the Company) holding Operating Group Units, directly or indirectly, are dissolved or merged with or into the Company, or an Underwritten Offering of Class A Shares, an In-Kind Exchange Distribution (including the corresponding exchange of an Operating Group Unit for Class A Shares in accordance with the Exchange Agreement).
		
	b)
	The following definition is hereby added in the proper alphabetical order:

“Exchange Date” has the meaning ascribed to such term in the Exchange Agreement.

		
	c)
	The definition of “In-Kind Exchange Distribution” is hereby amended and restated in its entirety as follows: 

“In-Kind Exchange Distribution” means a Pro Rata Exchange or a Non-Pro Rata Exchange accomplished by the distribution of Operating Group Units to all the limited partners of Holdings in the case of a Pro Rata Exchange or, in the case of a Non-Pro Rata Exchange, to those limited partners of Holdings on whose behalf such Non-Pro Rata Exchange is directed. 

		
	d)
	The definition of “Quarterly Exchange Date” is hereby deleted in its entirety.

		
	2.
	All references in the Agreement to “Quarterly Exchange Date” shall refer to “Exchange Date”.

		
	3.
	Effective Time. This Amendment shall be effective, and the provisions hereof shall become operative, at 12:01 a.m. on July 29, 2020 (the “Effective Time”) and no party shall be required to commence performance hereunder until the Effective Time.

		
	4.
	Miscellaneous. Sections 8.1 through 8.9 of the Agreement shall apply to this Amendment, mutatis mutandis. No amendment of the Agreement shall be required to the extent any entity becomes a successor of any of the parties thereto.

[Signatures on following pages]

IN WITNESS WHEREOF, the undersigned have caused this Amendment to be duly executed and delivered, all as of the date first set forth above.
APOLLO GLOBAL MANAGEMENT, INC.

By:     /s/ John J. Suydam                                              a 
    John J. Suydam 
    Chief Legal Officer
AP PROFESSIONAL HOLDINGS, L.P.
		
	By:
	BRH Holdings GP, Ltd., 
its General Partner

		
	By:
	/s/ John J. Suydam                                                   a 
John J. Suydam 
Vice President

BRH HOLDINGS, L.P.
		
	By:
	BRH Holdings GP, Ltd., 
its General Partner

By: /s/ John J. Suydam                                                 a      
John J. Suydam 
Vice President
/s/ Leon D. Black                                                     a 
Leon D. Black
/s/ Marc J. Rowan                                                    a 
Marc J. Rowan
/s/ Joshua J. Harris                                                  a 
Joshua J. Harris

BLACK FAMILY PARTNERS, L.P.
		
	By:
	Black Family GP, LLC, 
its General Partner

By: /s/ Leon D. Black                                                      a 
Leon D. Black 
Manager
MJR FOUNDATION LLC
		
	By: /s/ Marc J. Rowan                                                   
	 
Marc J. Rowan 
Manager

MJH PARTNERS, L.P.
		
	By:
	MJH Family LLC, 
its General Partner

		
	By: /s/ Joshua J. Harris                                                   
	 
Joshua J. Harris 
Sole Member

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]